Incyte Corporation has announced that Hervé Hoppenot, former President of Novartis Oncology, has been named President and Chief Executive Officer of Incyte, effective immediately.
Hoppenot will leave Novartis after more than ten years to join forces with the Delaware-based biopharmaceutical company, which has previously worked closely with Novartis for the development of cancer drugs.
Novartis said that Alessandro Riva, who serves as global head of oncology development and medical affairs, will take on the role of president on an interim basis until a permanent successor is identified.
Read the press release